Y-Trap, Inc. sued Bicara Therapeutics and Biocon Ltd in Massachusetts federal court in October 2024. Discovery is ongoing, and a patent office review Bicara requested was instituted on July 15, 2026.
Bicara priced 7,175,000 shares at $16.00 and pre-funded warrants for 2,200,000 more, with underwriting discounts of $9,000,000 on a total of $149,999,780.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $96.6 million, plus short-term investments of $400.7 million, $497.3 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Bicara Therapeutics
Has Bicara Therapeutics raised money recently?
Our latest story on this, dated Feb 24, 2026: "Bicara Therapeutics launches $150,000,000 offering, then prices at $16.00 a share". The story links the filing or release it is based on. Read the story.
Is Bicara Therapeutics involved in a lawsuit?
Our latest story on this, dated Aug 11, 2026: "Bicara and Biocon face Y-Trap inventorship suit over ficerafusp alfa patents". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Bicara Therapeutics?
Bicara Therapeutics Inc. trades under the ticker BCAX on NASDAQ.
Where is Bicara Therapeutics listed?
Bicara Therapeutics Inc. is listed on NASDAQ.
What is the SEC CIK of Bicara Therapeutics?
The SEC Central Index Key (CIK) for Bicara Therapeutics Inc. is 2023658. Its filings are on SEC EDGAR.
How many shares does Bicara Therapeutics have outstanding?
66,172,934 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Bicara Therapeutics listed under?
Our directory records Bicara Therapeutics Inc. under United States.
What does Bicara Therapeutics do?
Our directory classifies Bicara Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Bicara Therapeutics?
The ISIN recorded for Bicara Therapeutics Inc. is US0554771032.
Does aibio.space cover Bicara Therapeutics?
aibio.space lists Bicara Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Bicara Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Bicara Therapeutics profitable?
Bicara Therapeutics Inc. reported a net loss of $137.9 million for the fiscal year ended Dec 31, 2025, and used $106.8 million of cash in operations, per its annual report to the SEC.
How much cash does Bicara Therapeutics have?
$497.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Bicara Therapeutics (BCAX) stock news?
Our latest story on Bicara Therapeutics, dated Aug 11, 2026: "Bicara and Biocon face Y-Trap inventorship suit over ficerafusp alfa patents". Y-Trap, Inc. sued Bicara Therapeutics and Biocon Ltd in Massachusetts federal court in October 2024. Discovery is ongoing, and a patent office review Bicara requested was instituted on July 15, 2026. Source.
What is Bicara Therapeutics's market cap?
We do not publish live share prices. In its annual report, Bicara Therapeutics Inc. put the market value of shares held by non-affiliates (public float) at $376.7 million as of Jun 30, 2025.
Investor discussion: Bicara Therapeutics
Members talk about Bicara Therapeutics (BCAX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Bicara Therapeutics, newest first. Each line links the filing it comes from.
Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:BCAX on TradingView.
SEC filings and registration
SEC name
Bicara Therapeutics Inc.
CIK
2023658
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
BCAX (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
Phone
617-468-4219
Shares outstanding
66,172,934 as of 2026-08-06 (10-Q filed 2026-08-11)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Bicara Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BCAX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio